Skip to main content

Advertisement

Table 3 Day 1 and day 29 pharmacokinetic parameters (letrozole and nintedanib)

From: Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition

LET Mean Cmax (ng/ml) Mean Tmax (h) Mean AUC0-last (ng-h/ml) NINT Mean Cmax (ng/ml) Mean Tmax (h) Mean AUC0-last (ng-h/ml)
Level 1 day 1 100.2 0 2204 BS level 1 day 1 51 1.9 339
Level 1 day 29 89.4 4 2059 BS level 1 Day 29 50 1.1 519
Level 2 day 1 124.5 4 2782 BS level 2 day 1 65 2.0 599
Level 2 day 29 148.0 2 3170 BS level 2 day 29 92 2.0 941
  ZW level 1 day 1 24 1.9 200
ZW level 1 day 29 28 1.1 367
ZW level 2 day 1 41 3.3 413
ZW level 2 day 29 67 3.0 824
  1. LET letrozole, NINT nintedanib, BS BIBF1120-BS, ZW BIBF1202-ZW